{
    "abstract": "Background: Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) is a microarray skin patch comprised of a high-density array of microprojections dry-coated with vaccine that is being developed to address these shortcomings. Here we report a randomised, partly-blinded, placebo-controlled trial that represents the first use in humans of the NP to deliver a vaccine. Methods: Healthy volunteers were vaccinated once with one of the following: (1) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 \u00b5g haemagglutinin (HA) per dose), applied to the volar forearm (NP-HA/FA), n = 15; (2) NPs coated with split inactivated influenza virus (A/California/07/2009 [H1N1], 15 \u00b5g HA per dose), applied to the upper arm (NP-HA/UA), n = 15; (3) Fluvax\u00ae 2016 containing 15 \u00b5g of the same H1N1 HA antigen injected intramuscularly (IM) into the deltoid (IM-HA/D), n = 15; (4) NPs coated with excipients only, applied to the volar forearm (NP-placebo/FA), n = 5; (5) NPs coated with excipients only applied to the upper arm (NP-placebo/UA), n = 5; or (6) Saline injected IM into the deltoid (IM-placebo/D), n = 5. Antibody responses at days 0, 7, and 21 were measured by haemagglutination inhibition (HAI) and microneutralisation (MN) assays. Findings: NP vaccination was safe and acceptable; all adverse events were mild or moderate. Most subjects (55%) receiving patch vaccinations (HA or placebo) preferred the NP compared with their past experience of IM injection with N&S (preferred by 24%). The antigen-vaccinated groups had statistically higher HAI titres at day 7 and 21 compared with baseline (p < 0.0001), with no statistical differences between the treatment groups (p > 0.05), although the group sizes were small. The geometric mean HAI titres at day 21 for the NP-HA/FA, NP-HA/UA and IM-HA/D groups were: 335 (189\u2013593 95% CI), 160 (74\u2013345 95% CI), and 221 (129\u2013380 95% CI) respectively. A similar pattern of responses was seen with the MN assays. Application site reactions were mild or moderate, and more marked with the influenza vaccine NPs than with the placebo or IM injection. Interpretation: Influenza vaccination using the NP appeared to be safe, and acceptable in this first time in humans study, and induced similar immune responses to vaccination by IM injection.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1146/annurev-chembioeng-060816-101514",
            "firstpage": "177",
            "issn": "19475438",
            "lastpage": "200",
            "pmid": "28375775",
            "pub_year": 2017,
            "title": "Engineering microneedle patches for vaccination and drug delivery to skin",
            "volume": "8"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Marshall"
                },
                {
                    "first": "Laura J.",
                    "initial": "L.J.",
                    "last": "Sahm"
                },
                {
                    "first": "Anne C.",
                    "initial": "A.C.",
                    "last": "Moore"
                }
            ],
            "doi": "10.1080/21645515.2016.1171440",
            "firstpage": "2975",
            "issn": "21645515",
            "lastpage": "2983",
            "pmid": "27050528",
            "pub_year": 2016,
            "title": "The success of microneedle-mediated vaccine delivery into skin",
            "volume": "12"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Peter E.",
                    "initial": "P.E.",
                    "last": "Daddona"
                },
                {
                    "first": "James A.",
                    "initial": "J.A.",
                    "last": "Matriano"
                },
                {
                    "first": "Jaap",
                    "initial": "J.",
                    "last": "Mandema"
                },
                {
                    "first": "Yuh Fun",
                    "initial": "Y.F.",
                    "last": "Maa"
                }
            ],
            "doi": "10.1007/s11095-010-0192-9",
            "firstpage": "159",
            "issn": "07248741",
            "lastpage": "165",
            "pmid": "20567999",
            "pub_year": 2011,
            "title": "Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis",
            "volume": "28"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Sachiko",
                    "initial": "S.",
                    "last": "Hirobe"
                },
                {
                    "first": "Hiroaki",
                    "initial": "H.",
                    "last": "Azukizawa"
                },
                {
                    "first": "Kazuhiko",
                    "initial": "K.",
                    "last": "Matsuo"
                },
                {
                    "first": "You",
                    "initial": "Y.",
                    "last": "Zhai"
                },
                {
                    "first": "Ying Shu",
                    "initial": "Y.S.",
                    "last": "Quan"
                },
                {
                    "first": "Fumio",
                    "initial": "F.",
                    "last": "Kamiyama"
                },
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Suzuki"
                },
                {
                    "first": "Ichiro",
                    "initial": "I.",
                    "last": "Katayama"
                },
                {
                    "first": "Naoki",
                    "initial": "N.",
                    "last": "Okada"
                },
                {
                    "first": "Shinsaku",
                    "initial": "S.",
                    "last": "Nakagawa"
                }
            ],
            "doi": "10.1007/s11095-013-1092-6",
            "firstpage": "2664",
            "issn": "07248741",
            "lastpage": "2674",
            "pmid": "23775442",
            "pub_year": 2013,
            "title": "Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device",
            "volume": "30"
        },
        "b0025": {
            "authors": [
                {
                    "first": "James J.",
                    "initial": "J.J.",
                    "last": "Norman"
                },
                {
                    "first": "Jaya M.",
                    "initial": "J.M.",
                    "last": "Arya"
                },
                {
                    "first": "Maxine A.",
                    "initial": "M.A.",
                    "last": "McClain"
                },
                {
                    "first": "Paula M.",
                    "initial": "P.M.",
                    "last": "Frew"
                },
                {
                    "first": "Martin I.",
                    "initial": "M.I.",
                    "last": "Meltzer"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.076",
            "firstpage": "1856",
            "issn": "0264410X",
            "lastpage": "1862",
            "pmid": "24530146",
            "pub_year": 2014,
            "title": "Microneedle patches: Usability and acceptability for self-vaccination against influenza",
            "volume": "32"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Jaya",
                    "initial": "J.",
                    "last": "Arya"
                },
                {
                    "first": "Sebastien",
                    "initial": "S.",
                    "last": "Henry"
                },
                {
                    "first": "Haripriya",
                    "initial": "H.",
                    "last": "Kalluri"
                },
                {
                    "first": "Devin V.",
                    "initial": "D.V.",
                    "last": "McAllister"
                },
                {
                    "first": "Winston P.",
                    "initial": "W.P.",
                    "last": "Pewin"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1016/j.biomaterials.2017.02.040",
            "firstpage": "1",
            "issn": "01429612",
            "lastpage": "7",
            "pmid": "28285193",
            "pub_year": 2017,
            "title": "Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects",
            "volume": "128"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Griffin"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Elliott"
                },
                {
                    "first": "Kenia",
                    "initial": "K.",
                    "last": "Krauer"
                },
                {
                    "first": "Cristyn",
                    "initial": "C.",
                    "last": "Davies"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Rachel Skinner"
                },
                {
                    "first": "Christopher D.",
                    "initial": "C.D.",
                    "last": "Anderson"
                },
                {
                    "first": "Angus",
                    "initial": "A.",
                    "last": "Forster"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.10.021",
            "firstpage": "6676",
            "issn": "0264410X",
            "lastpage": "6684",
            "pmid": "29074201",
            "pub_year": 2017,
            "title": "Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects",
            "volume": "35"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Sachiko",
                    "initial": "S.",
                    "last": "Hirobe"
                },
                {
                    "first": "Hiroaki",
                    "initial": "H.",
                    "last": "Azukizawa"
                },
                {
                    "first": "Takaaki",
                    "initial": "T.",
                    "last": "Hanafusa"
                },
                {
                    "first": "Kazuhiko",
                    "initial": "K.",
                    "last": "Matsuo"
                },
                {
                    "first": "Ying Shu",
                    "initial": "Y.S.",
                    "last": "Quan"
                },
                {
                    "first": "Fumio",
                    "initial": "F.",
                    "last": "Kamiyama"
                },
                {
                    "first": "Ichiro",
                    "initial": "I.",
                    "last": "Katayama"
                },
                {
                    "first": "Naoki",
                    "initial": "N.",
                    "last": "Okada"
                },
                {
                    "first": "Shinsaku",
                    "initial": "S.",
                    "last": "Nakagawa"
                }
            ],
            "doi": "10.1016/j.biomaterials.2015.04.007",
            "firstpage": "50",
            "issn": "01429612",
            "lastpage": "58",
            "pmid": "25913250",
            "pub_year": 2015,
            "title": "Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch",
            "volume": "57"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Nadine G.",
                    "initial": "N.G.",
                    "last": "Rouphael"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Paine"
                },
                {
                    "first": "Regina",
                    "initial": "R.",
                    "last": "Mosley"
                },
                {
                    "first": "Sebastien",
                    "initial": "S.",
                    "last": "Henry"
                },
                {
                    "first": "Devin V.",
                    "initial": "D.V.",
                    "last": "McAllister"
                },
                {
                    "first": "Haripriya",
                    "initial": "H.",
                    "last": "Kalluri"
                },
                {
                    "first": "Winston",
                    "initial": "W.",
                    "last": "Pewin"
                },
                {
                    "first": "Paula M.",
                    "initial": "P.M.",
                    "last": "Frew"
                },
                {
                    "first": "Tianwei",
                    "initial": "T.",
                    "last": "Yu"
                },
                {
                    "first": "Natalie J.",
                    "initial": "N.J.",
                    "last": "Thornburg"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Kabbani"
                },
                {
                    "first": "Lilin",
                    "initial": "L.",
                    "last": "Lai"
                },
                {
                    "first": "Elena V.",
                    "initial": "E.V.",
                    "last": "Vassilieva"
                },
                {
                    "first": "Ioanna",
                    "initial": "I.",
                    "last": "Skountzou"
                },
                {
                    "first": "Richard W.",
                    "initial": "R.W.",
                    "last": "Compans"
                },
                {
                    "first": "Mark J.",
                    "initial": "M.J.",
                    "last": "Mulligan"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Beck"
                },
                {
                    "first": "Srilatha",
                    "initial": "S.",
                    "last": "Edupuganti"
                },
                {
                    "first": "Sheila",
                    "initial": "S.",
                    "last": "Heeke"
                },
                {
                    "first": "Colleen",
                    "initial": "C.",
                    "last": "Kelley"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Nesheim"
                }
            ],
            "doi": "10.1016/S0140-6736(17)30575-5",
            "firstpage": "649",
            "issn": "01406736",
            "lastpage": "658",
            "pmid": "28666680",
            "pub_year": 2017,
            "title": "The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial",
            "volume": "390"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Tarl W.",
                    "initial": "T.W.",
                    "last": "Prow"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Crichton"
                },
                {
                    "first": "Emily J.",
                    "initial": "E.J.",
                    "last": "Fairmaid"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Roberts"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Lorena E.",
                    "initial": "L.E.",
                    "last": "Brown"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1371/journal.pone.0010266",
            "issn": "19326203",
            "pmid": "20422002",
            "pub_year": 2010,
            "title": "Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model",
            "volume": "5"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Alexandra C.I.",
                    "initial": "A.C.I.",
                    "last": "Depelsenaire"
                },
                {
                    "first": "Stefano C.",
                    "initial": "S.C.",
                    "last": "Meliga"
                },
                {
                    "first": "Celia L.",
                    "initial": "C.L.",
                    "last": "Mcneilly"
                },
                {
                    "first": "Frances E.",
                    "initial": "F.E.",
                    "last": "Pearson"
                },
                {
                    "first": "Jacob W.",
                    "initial": "J.W.",
                    "last": "Coffey"
                },
                {
                    "first": "Oscar L.",
                    "initial": "O.L.",
                    "last": "Haigh"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Flaim"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1038/jid.2014.174",
            "firstpage": "2361",
            "issn": "0022202X",
            "lastpage": "2370",
            "pmid": "24714201",
            "pub_year": 2014,
            "title": "Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity",
            "volume": "134"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Zhang"
                },
                {
                    "first": "Hwee Ing",
                    "initial": "H.I.",
                    "last": "Ng"
                },
                {
                    "first": "Oscar L.",
                    "initial": "O.L.",
                    "last": "Haigh"
                },
                {
                    "first": "Sally R.",
                    "initial": "S.R.",
                    "last": "Yukiko"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.jconrel.2016.06.045",
            "firstpage": "35",
            "issn": "01683659",
            "lastpage": "41",
            "pmid": "27381247",
            "pub_year": 2016,
            "title": "Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8+ T cell responses",
            "volume": "237"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Hwee Ing",
                    "initial": "H.I.",
                    "last": "Ng"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.jconrel.2012.07.024",
            "firstpage": "477",
            "issn": "01683659",
            "lastpage": "484",
            "pmid": "22841796",
            "pub_year": 2012,
            "title": "Induction of potent CD8+ T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays",
            "volume": "162"
        },
        "b0070": {
            "authors": [
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Muller"
                },
                {
                    "first": "Frances E.",
                    "initial": "F.E.",
                    "last": "Pearson"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Christiana",
                    "initial": "C.",
                    "last": "Agyei-Yeboah"
                },
                {
                    "first": "Nick S.",
                    "initial": "N.S.",
                    "last": "Owens"
                },
                {
                    "first": "Simon R.",
                    "initial": "S.R.",
                    "last": "Corrie"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Crichton"
                },
                {
                    "first": "Jonathan C.J.",
                    "initial": "J.C.J.",
                    "last": "Wei"
                },
                {
                    "first": "William C.",
                    "initial": "W.C.",
                    "last": "Weldon"
                },
                {
                    "first": "M. Steven",
                    "initial": "M.S.",
                    "last": "Oberste"
                },
                {
                    "first": "Paul R.",
                    "initial": "P.R.",
                    "last": "Young"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1038/srep22094",
            "issn": "20452322",
            "pmid": "26911254",
            "pub_year": 2016,
            "title": "Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses",
            "volume": "6"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Hwee Ing",
                    "initial": "H.I.",
                    "last": "Ng"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Alexandra C.I.",
                    "initial": "A.C.I.",
                    "last": "Depelsenaire"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1038/srep29368",
            "issn": "20452322",
            "pmid": "27404789",
            "pub_year": 2016,
            "title": "Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing",
            "volume": "6"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Tarl W.",
                    "initial": "T.W.",
                    "last": "Prow"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Crichton"
                },
                {
                    "first": "Derek W.K.",
                    "initial": "D.W.K.",
                    "last": "Jenkins"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Roberts"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.jconrel.2009.06.029",
            "firstpage": "212",
            "issn": "01683659",
            "lastpage": "220",
            "pmid": "19577597",
            "pub_year": 2009,
            "title": "Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin",
            "volume": "139"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Clare A.",
                    "initial": "C.A.",
                    "last": "Primiero"
                },
                {
                    "first": "Sally R.",
                    "initial": "S.R.",
                    "last": "Yukiko"
                },
                {
                    "first": "Emily J.",
                    "initial": "E.J.",
                    "last": "Fairmaid"
                },
                {
                    "first": "Holly J.",
                    "initial": "H.J.",
                    "last": "Corbett"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Lorena E.",
                    "initial": "L.E.",
                    "last": "Brown"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.jconrel.2012.01.030",
            "firstpage": "215",
            "issn": "01683659",
            "lastpage": "221",
            "pmid": "22306334",
            "pub_year": 2012,
            "title": "Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses",
            "volume": "159"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Jesse",
                    "initial": "J.",
                    "last": "Bodle"
                },
                {
                    "first": "Erin E.",
                    "initial": "E.E.",
                    "last": "Verity"
                },
                {
                    "first": "Chi",
                    "initial": "C.",
                    "last": "Ong"
                },
                {
                    "first": "Kirsten",
                    "initial": "K.",
                    "last": "Vandenberg"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Shaw"
                },
                {
                    "first": "Ian G.",
                    "initial": "I.G.",
                    "last": "Barr"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Rockman"
                }
            ],
            "doi": "10.1111/j.1750-2659.2012.00375.x",
            "firstpage": "191",
            "issn": "17502640",
            "lastpage": "200",
            "pmid": "22583601",
            "pub_year": 2013,
            "title": "Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: An alternative method to single radial immunodiffusion",
            "volume": "7"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Thomas B.",
                    "initial": "T.B.",
                    "last": "Fitzpatrick"
                }
            ],
            "doi": "10.1001/archderm.1988.01670060015008",
            "firstpage": "869",
            "issn": "0003987X",
            "lastpage": "871",
            "pmid": "3377516",
            "pub_year": 1988,
            "title": "The Validity and Practicality of Sun-Reactive Skin Types I Through VI",
            "volume": "124"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Wagner"
                },
                {
                    "first": "Constanze",
                    "initial": "C.",
                    "last": "G\u00f6pfert"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Hammann"
                },
                {
                    "first": "Britta",
                    "initial": "B.",
                    "last": "Neumann"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Wood"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Newman"
                },
                {
                    "first": "Chantal",
                    "initial": "C.",
                    "last": "Wallis"
                },
                {
                    "first": "Nina",
                    "initial": "N.",
                    "last": "Alex"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Pfleiderer"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.02.077",
            "firstpage": "4113",
            "issn": "0264410X",
            "lastpage": "4122",
            "pmid": "22446639",
            "pub_year": 2012,
            "title": "Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-An effective EU regulatory approach",
            "volume": "30"
        },
        "b0105": {
            "authors": [
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Birchall"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Clemo"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Anstey"
                },
                {
                    "first": "Dai N.",
                    "initial": "D.N.",
                    "last": "John"
                }
            ],
            "doi": "10.1007/s11095-010-0101-2",
            "firstpage": "95",
            "issn": "07248741",
            "lastpage": "106",
            "pmid": "20238152",
            "pub_year": 2011,
            "title": "Microneedles in clinical practice-an exploratory study into the opinions of healthcare professionals and the public",
            "volume": "28"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Chris P.",
                    "initial": "C.P.",
                    "last": "Verschoor"
                },
                {
                    "first": "Pardeep",
                    "initial": "P.",
                    "last": "Singh"
                },
                {
                    "first": "Margaret L.",
                    "initial": "M.L.",
                    "last": "Russell"
                },
                {
                    "first": "Dawn M.E.",
                    "initial": "D.M.E.",
                    "last": "Bowdish"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Brewer"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Cyr"
                },
                {
                    "first": "Brian J.",
                    "initial": "B.J.",
                    "last": "Ward"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Loeb"
                }
            ],
            "doi": "10.1371/journal.pone.0131531",
            "issn": "19326203",
            "pmid": "26107625",
            "pub_year": 2015,
            "title": "Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children",
            "volume": "10"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Anto",
                    "initial": "A.",
                    "last": "Vrdoljak"
                },
                {
                    "first": "Evin A.",
                    "initial": "E.A.",
                    "last": "Allen"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Ferrara"
                },
                {
                    "first": "Nigel J.",
                    "initial": "N.J.",
                    "last": "Temperton"
                },
                {
                    "first": "Abina M.",
                    "initial": "A.M.",
                    "last": "Crean"
                },
                {
                    "first": "Anne C.",
                    "initial": "A.C.",
                    "last": "Moore"
                }
            ],
            "doi": "10.1016/j.jconrel.2016.01.019",
            "firstpage": "192",
            "issn": "01683659",
            "lastpage": "204",
            "pmid": "26774221",
            "pub_year": 2016,
            "title": "Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods",
            "volume": "225"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Etchart"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Hennino"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Friede"
                },
                {
                    "first": "Karima",
                    "initial": "K.",
                    "last": "Dahel"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Dupouy"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Goujon-Henry"
                },
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Nicolas"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Kaiserlian"
                }
            ],
            "doi": "10.1016/j.vaccine.2007.07.014",
            "firstpage": "6891",
            "issn": "0264410X",
            "lastpage": "6899",
            "pmid": "17764789",
            "pub_year": 2007,
            "title": "Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans",
            "volume": "25"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Xianfeng",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Germain J.P.",
                    "initial": "G.J.P.",
                    "last": "Fernando"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Crichton"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Flaim"
                },
                {
                    "first": "Sally R.",
                    "initial": "S.R.",
                    "last": "Yukiko"
                },
                {
                    "first": "Emily J.",
                    "initial": "E.J.",
                    "last": "Fairmaid"
                },
                {
                    "first": "Holly J.",
                    "initial": "H.J.",
                    "last": "Corbett"
                },
                {
                    "first": "Clare A.",
                    "initial": "C.A.",
                    "last": "Primiero"
                },
                {
                    "first": "Alexander B.",
                    "initial": "A.B.",
                    "last": "Ansaldo"
                },
                {
                    "first": "Ian H.",
                    "initial": "I.H.",
                    "last": "Frazer"
                },
                {
                    "first": "Lorena E.",
                    "initial": "L.E.",
                    "last": "Brown"
                },
                {
                    "first": "Mark A.F.",
                    "initial": "M.A.F.",
                    "last": "Kendall"
                }
            ],
            "doi": "10.1016/j.jconrel.2011.02.026",
            "firstpage": "349",
            "issn": "01683659",
            "lastpage": "355",
            "pmid": "21371510",
            "pub_year": 2011,
            "title": "Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization",
            "volume": "152"
        }
    },
    "body_text": [
        {
            "endOffset": 35999,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "There was no statistical difference in the HAI GMTs at day 21 between the NP-HA/FA, NP-HA/UA and IM-HA/D groups for each binary comparison between groups.",
            "startOffset": 35845,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41910,
            "parents": [],
            "secId": "s0085",
            "sentence": "These points will be investigated and addressed in future, larger clinical studies, as will the longevity of the immune response.",
            "startOffset": 41781,
            "title": "Discussion"
        },
        {
            "endOffset": 28903,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Twofold serum dilutions starting from 1:100 were prepared and 100 TCID50 of A/California/07/2009 virus (WHO Collaborating Centre, Australia) were added to each test well.",
            "startOffset": 28733,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 33032,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Some subjects (13% and 33% in the NP-HA/FA and NP-HA/UA groups, respectively) experienced mild or moderate skin flaking at the area of skin directly under the NP application site at day 3, and at day 7 (67% and 87% in the NP-HA/FA and NP-HA/UA groups, respectively).",
            "startOffset": 32766,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 25898,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Subjects received a single vaccination at day 0, given to the non-dominant arm.",
            "startOffset": 25819,
            "title": "Study procedures"
        },
        {
            "endOffset": 24262,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The study was approved by the QIMR-Berghofer Medical Research Institute (Brisbane, Australia) Human Research Ethics Committee, and conducted in accordance with the National Statement of Ethical Conduct in Human Research (2007), the Australian National Health and Medical Research Council guidelines, and Good Clinical Practice (CPMP/ICH/135/95), as adopted by the Therapeutic Goods Administration (2000).",
            "startOffset": 23858,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 36908,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "There was no increase in MN titre in any of the placebo groups following vaccination.",
            "startOffset": 36823,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 42667,
            "parents": [],
            "secId": "s0085",
            "sentence": "To this end, a number of key technological developments have been put in place for NPs since this study was conducted.",
            "startOffset": 42549,
            "title": "Discussion"
        },
        {
            "endOffset": 36822,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The MN GMT at day 21 for the NP-HA/FA, NP-HA/UA and IM-HA/D groups were: 6703 (3534\u201312,713, 95% CI), 2211 (1057\u20134624, 95% CI), and 4032 (1854\u20138767, 95% CI) respectively (Supplementary Table 3) and there was no statistical difference in the GMT between the different treatment groups.",
            "startOffset": 36539,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41147,
            "parents": [],
            "secId": "s0085",
            "sentence": "Thus, immune responses to NP-delivered vaccine were measured to only one influenza subtype.",
            "startOffset": 41056,
            "title": "Discussion"
        },
        {
            "endOffset": 26287,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The NP was applied to the skin with the applicator and left on the skin for 2 min before being removed.",
            "startOffset": 26184,
            "title": "Study procedures"
        },
        {
            "endOffset": 40417,
            "parents": [],
            "secId": "s0085",
            "sentence": "Some of the analyses (GMT and fold-increase in GMT, Supplementary Table 3) suggested higher antibody responses in the forearm NP group than the IM group, and lower titres in the upper arm NP group; these differences were not statistically significant however.",
            "startOffset": 40158,
            "title": "Discussion"
        },
        {
            "endOffset": 29505,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "These tests were used to assess statistical differences, where significance is assumed p < 0.05.",
            "startOffset": 29409,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39932,
            "parents": [],
            "secId": "s0085",
            "sentence": "The HAI and MN titres induced were not significantly different between the different modes of vaccination, indicating that, at the standard dose of 15 \u00b5g HA, the antibody responses induced by the NP were similar to those induced by IM injection, with the caveat that the group sizes in this study were small.",
            "startOffset": 39624,
            "title": "Discussion"
        },
        {
            "endOffset": 44059,
            "parents": [],
            "secId": "s0095",
            "sentence": "PG, IHF and AHF supervised the study.",
            "startOffset": 44022,
            "title": "Contributors"
        },
        {
            "endOffset": 21579,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The separate applicator was a hand-held spring-powered, auto-disabling device (Fig. 1C and D).",
            "startOffset": 21485,
            "title": "Nanopatch manufacture"
        },
        {
            "endOffset": 27959,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Serum samples were collected for testing in haemagglutination inhibition (HAI) and microneutralisation (MN) assays (360biolabs Pty Ltd, Australia) on days 0 (pre-vaccination), 7, and 21.",
            "startOffset": 27773,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 30547,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Of the subjects receiving vaccine, 8 of 16 (50%) NP-HA/FA subjects, 9 of 15 (60%) NP-HA/UA subjects, and 5 out of 15 (33%) IM-HA/D subjects reported at least one AE, and a similar proportion of placebo recipients, 8 of 15 (53%), reported at least one AE.",
            "startOffset": 30293,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 27745,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 27744,
                    "startOffset": 27741
                }
            },
            "secId": "s0035",
            "sentence": "Potential subject bias against N&S was addressed as part the screening questionnaire [7].",
            "startOffset": 27656,
            "title": "Qualitative acceptability assessment"
        },
        {
            "endOffset": 36250,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The percentage of subjects seroconverting after treatment (i.e. with HAI titre <10 prevaccination and \u22651:40 at day 21, or showing a 4-fold increase in titre following vaccination) were: NP-HA/FA 12 out of 15 (80%); NP-HA/UA 9 (60%); IM-HA/D 12 (80%).",
            "startOffset": 36000,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21484,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Briefly, NPs were manufactured from silicon wafers, dry-etched, and diced to give individual patches of 10 \u00d7 10 mm with microprojection arrays (10,000/cm2) of 250 \u00b5m length (Fig. 1A and B).",
            "startOffset": 21295,
            "title": "Nanopatch manufacture"
        },
        {
            "endOffset": 40157,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 40156,
                    "startOffset": 40149
                },
                "b0055": {
                    "endOffset": 40156,
                    "startOffset": 40149
                },
                "b0060": {
                    "endOffset": 40156,
                    "startOffset": 40149
                },
                "b0065": {
                    "endOffset": 40156,
                    "startOffset": 40149
                },
                "b0070": {
                    "endOffset": 40156,
                    "startOffset": 40149
                },
                "b0075": {
                    "endOffset": 40156,
                    "startOffset": 40149
                }
            },
            "secId": "s0085",
            "sentence": "A single dose level of HA was selected for the study (estimated to be a delivered dose of 15 \u00b5g), so it was not possible to determine whether NP administration resulted in dose-sparing, as seen in preclinical models [10\u201315].",
            "startOffset": 39933,
            "title": "Discussion"
        },
        {
            "endOffset": 30848,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "All AEs were mild or moderate with the exception of one serious AE, a spontaneous abortion that was not considered related to treatment.",
            "startOffset": 30712,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 29979,
            "parents": [],
            "secId": "s0055",
            "sentence": "Between 29 June and 12 August 2016, 61 subjects were enrolled, randomly assigned to a treatment group and were vaccinated.",
            "startOffset": 29857,
            "title": "Results"
        },
        {
            "endOffset": 34815,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 34814,
                    "startOffset": 34811
                }
            },
            "secId": "s0075",
            "sentence": "The questionnaire and interview results were consistent with those obtained in the previous study with NPs without antigen [7].",
            "startOffset": 34688,
            "title": "Acceptability questionnaire and interviews"
        },
        {
            "endOffset": 36426,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "MN assays were performed to assess levels of functional anti-influenza antibodies (Fig. 6B).",
            "startOffset": 36334,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34028,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "0.8 (\u2212.04 to 1.64 95% CI) for the NP-HA/FA, NP-HA/UA and IM-HA/D groups respectively.",
            "startOffset": 33943,
            "title": "Pain at application site"
        },
        {
            "endOffset": 40769,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 40744,
                    "startOffset": 40741
                },
                "b0045": {
                    "endOffset": 40768,
                    "startOffset": 40765
                }
            },
            "secId": "s0085",
            "sentence": "The overall finding that the MAP-induced antibody responses were similar in magnitude to those following IM injection, was similar to the results reported by Hirobe et al. [8] and Rouphael et al. [9].",
            "startOffset": 40569,
            "title": "Discussion"
        },
        {
            "endOffset": 21878,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "cGMP-grade, monovalent, inactivated, split influenza A/California/07/2009 (H1N1)-like virus antigen (Seqirus Pty Ltd, Australia.",
            "startOffset": 21750,
            "title": "Vaccine"
        },
        {
            "endOffset": 33942,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The mean scores for the groups receiving vaccine were 1.1 (0.51\u20131.61 95% CI), 0.9 (0.24\u20131.50 95% CI).",
            "startOffset": 33841,
            "title": "Pain at application site"
        },
        {
            "endOffset": 43381,
            "parents": [],
            "secId": "s0085",
            "sentence": "Finally, in this study, a separate applicator was used, whereas in the commercial embodiment of the device, the NP and applicator will be in an integrated, single-use device.",
            "startOffset": 43207,
            "title": "Discussion"
        },
        {
            "endOffset": 27313,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Pain scores were collected 10 min after the patch removal and at all outpatient-assessments using a visual analogue scale (VAS, QPharm) with 0 = no pain; 5 = moderate pain; 10 = worst pain possible.",
            "startOffset": 27115,
            "title": "Study procedures"
        },
        {
            "endOffset": 38105,
            "parents": [],
            "secId": "s0085",
            "sentence": "It is likely that any erythema and itchiness reflected inflammatory processes in the skin involved in the induction of immune responses, which would be more visible with NP delivery than IM injection as they occur closer to the surface of the skin.",
            "startOffset": 37857,
            "title": "Discussion"
        },
        {
            "endOffset": 41055,
            "parents": [],
            "secId": "s0085",
            "sentence": "For this initial test of the NP in humans, a monovalent influenza vaccine (H1N1) was used for simplicity, rather than the tri-valent formulation administered IM.",
            "startOffset": 40894,
            "title": "Discussion"
        },
        {
            "endOffset": 23574,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccine for the IM-HA/D group was the commercially-available trivalent Fluvax\u00ae 2016 Southern hemisphere formulation (Seqirus Pty Ltd, Australia batch number 0906-46202), containing A/California/07/2009 (H1N1-like), A/New Caledonia/71/2014 (NYMC X-257A) (H3N2-like) and B/Brisbane/60/2008, all at 15 \u03bcg HA per dose.",
            "startOffset": 23256,
            "title": "Vaccine"
        },
        {
            "endOffset": 20018,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 19883,
                    "startOffset": 19880
                },
                "b0020": {
                    "endOffset": 20017,
                    "startOffset": 20012
                },
                "b0025": {
                    "endOffset": 20017,
                    "startOffset": 20012
                },
                "b0030": {
                    "endOffset": 20017,
                    "startOffset": 20012
                },
                "b0035": {
                    "endOffset": 20017,
                    "startOffset": 20012
                }
            },
            "secId": "s0005",
            "sentence": "MAPs have also been evaluated in clinical trials for delivery of non-vaccine drugs [3], and in a limited number of clinical studies evaluating the tolerability and acceptability of MAPs, but without vaccine antigen [4\u20137].",
            "startOffset": 19797,
            "title": "Introduction"
        },
        {
            "endOffset": 38437,
            "parents": [],
            "secId": "s0085",
            "sentence": "Erythema at the NP-application site took longer to resolve with HA-antigen-containing NPs compared with placebo NPs, possibly due to the initial innate inflammatory response to the antigen, and/or activation of antigen specific T cells resident in the skin.",
            "startOffset": 38180,
            "title": "Discussion"
        },
        {
            "endOffset": 39062,
            "parents": [],
            "secId": "s0085",
            "sentence": "The scores for pain at the application site appeared to be higher with the HA-antigen-containing NPs than the placebo in our study.",
            "startOffset": 38931,
            "title": "Discussion"
        },
        {
            "endOffset": 19587,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, this method has drawbacks, including fear of needles, risk of needle-stick injury, the need for safe disposal of sharps waste, the need to reconstitute lyophilised vaccines, and the requirement for healthcare professionals to administer injections.",
            "startOffset": 19330,
            "title": "Introduction"
        },
        {
            "endOffset": 23256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The investigational A/California/07/2009 (H1N1) vaccine on the NP met its target specifications and was administered to patients within three months of production.",
            "startOffset": 23093,
            "title": "Vaccine"
        },
        {
            "endOffset": 29282,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Intragroup comparisons were performed using Wilcoxon signed-rank test to assess the immune responses post treatment, and intergroup comparisons were made by using the non-parametric Kruskal-Wallis test (One-way ANOVA on ranks).",
            "startOffset": 29055,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38700,
            "parents": [],
            "secId": "s0085",
            "sentence": "It was not reported whether this resulted in a reaction at the original patch application site.",
            "startOffset": 38605,
            "title": "Discussion"
        },
        {
            "endOffset": 24488,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Universal Trial Number U1111-1184-5260.",
            "startOffset": 24449,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 30292,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A total of 40 adverse events (AEs) were reported by 30 subjects (Table 1).",
            "startOffset": 30218,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 37209,
            "parents": [],
            "secId": "s0085",
            "sentence": "This study was the first use of the NP to deliver a vaccine antigen to the skin of human volunteers.",
            "startOffset": 37109,
            "title": "Discussion"
        },
        {
            "endOffset": 40858,
            "parents": [],
            "secId": "s0085",
            "sentence": "These two studies used DMNs and involved longer patch wear times than needed for the NP.",
            "startOffset": 40770,
            "title": "Discussion"
        },
        {
            "endOffset": 29408,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Mann-Whitney test was used to compare intergroup skin irritation index scores in response to vaccination or application site.",
            "startOffset": 29283,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38604,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 38455,
                    "startOffset": 38452
                }
            },
            "secId": "s0085",
            "sentence": "Hirobe et al. [8] also reported peak application site redness 2 days after application of DMNs, that lasted for at least 21 days, and then a second patch was applied.",
            "startOffset": 38438,
            "title": "Discussion"
        },
        {
            "endOffset": 35663,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "There was an increase in the HAI geometric mean titre (GMT) compared to baseline for the NP-HA/FA, NP-HA/UA and IM-HA/D groups at day 7 (p \u2264 0.0022 in all groups) and day 21 (p < 0.0001 in all groups) post vaccination, while there was no increase in HAI titre in any of the placebo groups following vaccination (Fig. 6A).",
            "startOffset": 35342,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38179,
            "parents": [],
            "secId": "s0085",
            "sentence": "Tenderness and pain are generally observed with IM injection of vaccines.",
            "startOffset": 38106,
            "title": "Discussion"
        },
        {
            "endOffset": 42548,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 42383,
                    "startOffset": 42376
                },
                "b0035": {
                    "endOffset": 42383,
                    "startOffset": 42376
                },
                "b0045": {
                    "endOffset": 42383,
                    "startOffset": 42376
                }
            },
            "secId": "s0085",
            "sentence": "Given the encouraging immunogenicity and acceptability data from this and other recent clinical MAP vaccination studies [6,7,9], the challenge now facing all vaccine MAP developers is to scale-up manufacturing processes to enable production millions of devices at an acceptable cost of goods.",
            "startOffset": 42256,
            "title": "Discussion"
        },
        {
            "endOffset": 44021,
            "parents": [],
            "secId": "s0095",
            "sentence": "CMJ, GJF, JH, KW, MP, RSS, CD, JB, SR, CDA, and AHF analysed and interpreted the data.",
            "startOffset": 43935,
            "title": "Contributors"
        },
        {
            "endOffset": 24787,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Exclusion criteria included influenza vaccination or known influenza infection during the previous year (to minimise baseline antibody titres).",
            "startOffset": 24644,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 36334,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "There were no seroconversions in any of the placebo groups (Supplementary Table 3).",
            "startOffset": 36251,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28732,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Briefly, serum samples were heat inactivated at 56 \u00b0C for 30 min.",
            "startOffset": 28667,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 23762,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Pre-filled syringes containing sterile saline solution (0.9% sodium chloride), were provided by Q-Pharm Pty Ltd (Australia, lot 0906-46202) as the IM placebo (for the IM-placebo/D group).",
            "startOffset": 23575,
            "title": "Vaccine"
        },
        {
            "endOffset": 27021,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 27020,
                    "startOffset": 27017
                }
            },
            "secId": "s0030",
            "sentence": "Skin reactions were assessed for: erythema (0 = none; 1 = very slight; 2 = well-defined; 3 = moderate to severe; 4 = severe [beet red]) and oedema (0 = none; 1 = very slight; 2 = slight; 3 = moderate [raised approximately 1 mm]; 5 = severe), and a skin irritation index (SII) was calculated, as the sum of the erythema and oedema scores as described previously [7].",
            "startOffset": 26656,
            "title": "Study procedures"
        },
        {
            "endOffset": 22310,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 22309,
                    "startOffset": 22305
                }
            },
            "secId": "s0020",
            "sentence": "The resulting solution (41 \u00b5L, containing 40 \u00b5g HA) was applied onto each NP and dried using sterile filtered nitrogen [16].",
            "startOffset": 22186,
            "title": "Vaccine"
        },
        {
            "endOffset": 32765,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Mild itching was recorded by 13% and 7% of NP-HA/FA and NP-HA/UA recipients, respectively, at day 7.",
            "startOffset": 32665,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 34517,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The highest pain score recorded was \u20186\u2019, for an IM vaccination, 10-min post administration.",
            "startOffset": 34426,
            "title": "Pain at application site"
        },
        {
            "endOffset": 22185,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "MPH Lot # M09061498100V) was combined with excipients: 1% w/v hypromellose (Shin-Etsu Chemical Company Ltd, Japan); 0.72% w/v trehalose (as dihydrate) (Pfanstiehl, Germany); and Dulbecco\u2019s phosphate-buffered saline (DPBS) (Sigma Aldrich, USA) to give a final formulation of 0.976 \u00b5g/\u00b5L haemagglutinin (HA).",
            "startOffset": 21879,
            "title": "Vaccine"
        },
        {
            "endOffset": 28205,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "TRBC were diluted to 1% v/v in PBS prior to testing.",
            "startOffset": 28153,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 21106,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21105,
                    "startOffset": 21102
                }
            },
            "secId": "s0005",
            "sentence": "NPs were found to be safe and well-tolerated, and preferred to N&S by the majority of subjects [7].",
            "startOffset": 21007,
            "title": "Introduction"
        },
        {
            "endOffset": 26485,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Subjects were monitored by clinic safety assessment visits at days 0, 3, 7, 21, and 28; and phone calls at days 1, 2, and 14.",
            "startOffset": 26360,
            "title": "Study procedures"
        },
        {
            "endOffset": 23092,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 23091,
                    "startOffset": 23087
                }
            },
            "secId": "s0020",
            "sentence": "The A/California/07/2009 HA antigen coated onto NPs was shown to be stable (the average HA content of coated NPs was \u226570 and \u2264130% of the potency of the original coating solution) for \u22653 months at 2\u20138 \u00b0C following coating onto NPs by enzyme-linked immunoassay [18].",
            "startOffset": 22827,
            "title": "Vaccine"
        },
        {
            "endOffset": 26583,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "On day 0, all vaccination sites were assessed at 10 min, 1 and 2 h after NP or IM administration.",
            "startOffset": 26486,
            "title": "Study procedures"
        },
        {
            "endOffset": 33717,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "All patches and microprojections appeared intact after removal from skin as assessed by scanning electron microscopy (SEM) (data not shown).",
            "startOffset": 33577,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 34425,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Overall 55% of NP-HA/FA and NP-HA/UA applications were scored as \u20180\u2019 (no pain), compared to 60% of NP-placebo/FA and NP-placebo/UA applications, 73% of the IM-HA/D vaccinations, and 100% IM-placebo/D injections.",
            "startOffset": 34214,
            "title": "Pain at application site"
        },
        {
            "endOffset": 25995,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Application sites were selected to be free from scarring, tattoos, skin conditions, and sunburn.",
            "startOffset": 25899,
            "title": "Study procedures"
        },
        {
            "endOffset": 41366,
            "parents": [],
            "secId": "s0085",
            "sentence": "It is also possible that the response to the H1N1 antigen given IM would be different when administered as a monovalent or trivalent formulation, although we are not aware of any data to suggest this might be the case.",
            "startOffset": 41148,
            "title": "Discussion"
        },
        {
            "endOffset": 24856,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The study was a randomized, partly-blinded, placebo-controlled trial.",
            "startOffset": 24787,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 41780,
            "parents": [],
            "secId": "s0085",
            "sentence": "It should be stressed that the number of subjects in each group was small, therefore any conclusions regarding the relative immunogenicity of the different treatment groups need to be made in this context of this limitation.",
            "startOffset": 41556,
            "title": "Discussion"
        },
        {
            "endOffset": 31141,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "This was considered to be unrelated to vaccination, but the subject withdrew from the study.",
            "startOffset": 31049,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 40893,
            "parents": [],
            "secId": "s0085",
            "sentence": "This study had several limitations.",
            "startOffset": 40858,
            "title": "Discussion"
        },
        {
            "endOffset": 20230,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 20229,
                    "startOffset": 20224
                },
                "b0045": {
                    "endOffset": 20229,
                    "startOffset": 20224
                }
            },
            "secId": "s0005",
            "sentence": "However to date, only two clinical studies using MAPs to deliver a vaccine to human skin have been published, both of which used dissolving microneedles (DMNs) and trivalent split influenza virus vaccines [8,9].",
            "startOffset": 20019,
            "title": "Introduction"
        },
        {
            "endOffset": 37562,
            "parents": [],
            "secId": "s0085",
            "sentence": "It was however expected that reactogenicity at the site of NP application would be more apparent than seen with IM injection due to the vaccine being delivered very close to the skin surface.",
            "startOffset": 37371,
            "title": "Discussion"
        },
        {
            "endOffset": 44281,
            "parents": [],
            "secId": "s0100",
            "sentence": "JH, GJF and CDA have received consultancy fees from Vaxxas Pty Ltd.",
            "startOffset": 44214,
            "title": "Declaration of interests"
        },
        {
            "endOffset": 33576,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "All application site reactions recorded were mild or moderate, with the exception of a single subject with \u2018severe\u2019 colouration at 10 min after application (NP-HA/FA group) graded as 3 on a scale of 0 to 5.",
            "startOffset": 33370,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 20390,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaxxas Pty Ltd is developing the Nanopatch\u2122 (NP), a MAP with a high density of solid microprojections onto which the vaccine formulation is dispensed and dried.",
            "startOffset": 20230,
            "title": "Introduction"
        },
        {
            "endOffset": 35245,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "HAI titre was used as the primary measure of immunogenicity.",
            "startOffset": 35185,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28470,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "TRBC were added and incubated for a further 30 min at RT.",
            "startOffset": 28413,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 29032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Prevention of infection of MDCK cells by A/California/07/2009 virus was tested using ELISA detection of influenza nucleoprotein.",
            "startOffset": 28904,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 41555,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 41554,
                    "startOffset": 41547
                },
                "b0120": {
                    "endOffset": 41554,
                    "startOffset": 41547
                }
            },
            "secId": "s0085",
            "sentence": "In addition, assays were not performed to determine whether NPs induced qualitatively different immune responses, as have been reported before with MAPs or transcutaneous delivery [23,24].",
            "startOffset": 41367,
            "title": "Discussion"
        },
        {
            "endOffset": 42256,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 42255,
                    "startOffset": 42251
                }
            },
            "secId": "s0085",
            "sentence": "In a previous study, influenza vaccine coated onto NPs in a similar formulation to the one used in this study, was shown to be stable for at least 6 months at room temperature when stored protected from moisture [25].",
            "startOffset": 42039,
            "title": "Discussion"
        },
        {
            "endOffset": 21749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccine-coated NPs for the NP-HA/FA and NP-HA/UA groups were produced in an aseptic process.",
            "startOffset": 21657,
            "title": "Vaccine"
        },
        {
            "endOffset": 33370,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Only one subject (NP-HA/FA) recorded pin-point bleeding from 10 min to 2 h post-application.",
            "startOffset": 33278,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 35844,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The HAI GMTs at day 21 for the NP-HA/FA, NP-HA/UA and IM-HA/D groups were: 335 (189\u2013593 95% CI), 160 (74\u2013345 95% CI), and 221 (129\u2013380 95% CI) respectively (Supplementary Table 3).",
            "startOffset": 35664,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21294,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21293,
                    "startOffset": 21290
                }
            },
            "secId": "s0015",
            "sentence": "The NP and applicator were identical to those used in a previous study [7].",
            "startOffset": 21219,
            "title": "Nanopatch manufacture"
        },
        {
            "endOffset": 20498,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 20497,
                    "startOffset": 20494
                }
            },
            "secId": "s0005",
            "sentence": "The current configuration of the NP used and its applicator were identical to those studied previously [7].",
            "startOffset": 20391,
            "title": "Introduction"
        },
        {
            "endOffset": 24323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Written informed consent was obtained from all participants.",
            "startOffset": 24263,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 28152,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Serum samples for HAI were treated with receptor destroying enzyme (Denka Seiken Co Ltd, Japan) and adsorbed to washed, packed turkey red blood cells (TRBC) for 30 min at room temperature (RT).",
            "startOffset": 27959,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 34213,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Scores in placebo recipients were similar; 0.8 (\u22120.16 to 1.76 95% CI), 0.8 (\u22120.16 to 1.76 95% CI) and 0 (no pain recorded) for the NP-placebo/FA, NP-placebo/UA and IM-placebo/D groups.",
            "startOffset": 34029,
            "title": "Pain at application site"
        },
        {
            "endOffset": 44213,
            "parents": [],
            "secId": "s0100",
            "sentence": "JH and IHF are both members of the Scientific Advisory Board of Vaxxas Pty Ltd.",
            "startOffset": 44134,
            "title": "Declaration of interests"
        },
        {
            "endOffset": 26083,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The area for application was marked, swabbed using a 70% ethanol swab and photographed.",
            "startOffset": 25996,
            "title": "Study procedures"
        },
        {
            "endOffset": 31837,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Analysis of the skin irritation index (SII) scores indicated that the erythema response predominated over oedema and lasted longer (Fig. 4A and B).",
            "startOffset": 31690,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 20916,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20802,
                    "startOffset": 20798
                }
            },
            "secId": "s0005",
            "sentence": "The high density of microprojections might have a physical immune-enhancing effect, resulting in dose-sparing [11] but this feature means that high velocity application with an applicator is required to achieve skin penetration.",
            "startOffset": 20688,
            "title": "Introduction"
        },
        {
            "endOffset": 30190,
            "parents": [],
            "secId": "s0055",
            "sentence": "There were no substantial differences between the three groups in terms of demographic profile (Supplementary Table 1).",
            "startOffset": 30071,
            "title": "Results"
        },
        {
            "endOffset": 39624,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 39623,
                    "startOffset": 39619
                }
            },
            "secId": "s0085",
            "sentence": "Future studies will investigate whether the NP wear time can be further reduced which might further increase compliance [21].",
            "startOffset": 39499,
            "title": "Discussion"
        },
        {
            "endOffset": 31572,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0035": {
                    "endOffset": 31571,
                    "startOffset": 31568
                }
            },
            "secId": "s0065",
            "sentence": "This was consistent with previous observations with placebo NPs [7].",
            "startOffset": 31504,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 39238,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, the majority of subjects did not find NP administration painful, and a slight majority preferred NP to N&S injections, potentially reducing resistance to vaccination.",
            "startOffset": 39063,
            "title": "Discussion"
        },
        {
            "endOffset": 25800,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Healthy females and males, aged 18\u201345 years, non-pregnant and non-nursing (N = 61), with a BMI in the range of 18\u201330 kg/m2 were randomly allocated into one of six vaccination groups: (1) NPs coated with inactivated split influenza virus (A/California/07/2009 (H1N1), 15 \u00b5g haemagglutinin (HA) per dose), applied to the volar forearm (NP-HA/FA), n = 15; (2) NPs coated with the same inactivated split influenza virus (A/California/07/2009 (H1N1), 15 \u00b5g HA per dose), applied to the upper arm, above the acromial prominence of the deltoid muscle, (NP-HA/UA), n = 15; or (3) Fluvax\u00ae 2016 containing 15 \u00b5g of the same H1 HA antigen injected intramuscularly (IM) into the deltoid (IM-HA/D), n = 15; (4) NPs coated with excipients only, applied to the volar forearm (NP-placebo/FA), n = 5; (5) NPs coated with excipients only applied to the upper arm (NP-placebo/UA), n = 5; or (6) Saline injected IM into the deltoid (IM-placebo/D), n = 5 (Fig. 2).",
            "startOffset": 24857,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 30972,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "No clinically significant events were observed with respect to clinical laboratory tests, vital signs or aural temperature.",
            "startOffset": 30849,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 43596,
            "parents": [],
            "secId": "s0090",
            "sentence": "In this small first time in human study, the NP vaccine delivery system appeared to be safe, well tolerated by the subjects receiving the vaccination, and induced similar immune responses as IM injection.",
            "startOffset": 43392,
            "title": "Conclusion"
        },
        {
            "endOffset": 23824,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccine was within its shelf-life when used in the study.",
            "startOffset": 23763,
            "title": "Vaccine"
        },
        {
            "endOffset": 26655,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Photographs of the application sites were taken at every clinic review.",
            "startOffset": 26584,
            "title": "Study procedures"
        },
        {
            "endOffset": 24643,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 24588,
                    "startOffset": 24584
                }
            },
            "secId": "s0025",
            "sentence": "The study was restricted to fair-skinned subjects (types I, II or III on the Fitzpatrick scale) [19], to facilitate clear observation of the skin response.",
            "startOffset": 24488,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 32330,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Comparing the skin response at application sites on the forearm or upper arm at each timepoint, there was a greater decrease in erythema at the upper arm sites at days 21 and 28 (Mann-Whitney Test, p < 0.05) (Fig. 4D).",
            "startOffset": 32112,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 28412,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Twofold serum dilutions starting from 1:10 were prepared and 4 HA Units/25 \u00b5L of A/California/07/2009 virus (WHO Collaborating Centre, Australia) were added to each test well and incubated for 45 min at RT.",
            "startOffset": 28206,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 44133,
            "parents": [],
            "secId": "s0100",
            "sentence": "CMJ, KW, and AHF are employees of Vaxxas Pty. Ltd.",
            "startOffset": 44083,
            "title": "Declaration of interests"
        },
        {
            "endOffset": 21187,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here we report the first clinical study evaluating vaccine delivery with the NP.",
            "startOffset": 21107,
            "title": "Introduction"
        },
        {
            "endOffset": 29579,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Analyses were performed with GraphPad PRISM version 7.03 (La Jolla, USA).",
            "startOffset": 29506,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27114,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Induration, bruising, skin flaking, discolouration, itching and bleeding were also assessed.",
            "startOffset": 27022,
            "title": "Study procedures"
        },
        {
            "endOffset": 32664,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The application sites were also monitored for spreading redness around the application site and colouration, itching, skin flaking, bleeding, induration, seepage and bruising (Supplementary Table 2).",
            "startOffset": 32465,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 38931,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 38898,
                    "startOffset": 38895
                },
                "b0035": {
                    "endOffset": 38823,
                    "startOffset": 38820
                },
                "b0045": {
                    "endOffset": 38930,
                    "startOffset": 38927
                }
            },
            "secId": "s0085",
            "sentence": "Overall, the tolerability and acceptability findings with NPs were similar to those seen with uncoated and placebo NPs [7], and similar to those reported for DMNs without antigen by Arya et al. [6], and with influenza antigen [9].",
            "startOffset": 38701,
            "title": "Discussion"
        },
        {
            "endOffset": 28666,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 28665,
                    "startOffset": 28661
                }
            },
            "secId": "s0040",
            "sentence": "MN assays were conducted according to published methodology [20].",
            "startOffset": 28601,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 33163,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Placebo recipients also experienced mild or moderate skin flaking (60% of subjects in the NP-placebo/FA and NP-placebo UA groups).",
            "startOffset": 33033,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 37098,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "In both the HAI and MN assays, there was a slight trend for the NP-HA/FA group titres to be higher than those for the NP-HA/UA or IM-HA/D groups, but this was not statistically significant.",
            "startOffset": 36909,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 27655,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Interviews were digitally recorded, transcribed verbatim, and de-identified prior to analysis.",
            "startOffset": 27561,
            "title": "Qualitative acceptability assessment"
        },
        {
            "endOffset": 33277,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Only one subject (NP-placebo/FA) experienced induration; classified as mild.",
            "startOffset": 33201,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 37856,
            "parents": [],
            "secId": "s0085",
            "sentence": "There were more local reactions at the site of NP application than were seen with IM injection as expected, but these were self-limiting and mild or moderate in intensity.",
            "startOffset": 37685,
            "title": "Discussion"
        },
        {
            "endOffset": 43843,
            "parents": [],
            "secId": "s0095",
            "sentence": "All authors contributed to the design of the study and approved the final version of the article.",
            "startOffset": 43746,
            "title": "Contributors"
        },
        {
            "endOffset": 33200,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "It was not seen at later timepoints.",
            "startOffset": 33164,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 35341,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "All subjects were included in the analysis, irrespective of their baseline HAI titres at day 0.",
            "startOffset": 35246,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36538,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "As with the HAI results, all groups receiving the vaccine showed an increase in MN titres at days 7 and day 21.",
            "startOffset": 36427,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22688,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Placebo NPs (for the NP-placebo/FA and NP-placebo/UA groups) were coated with formulation excipients without antigen and gamma-sterilised (\u226525 kGy, Steritech, Australia).",
            "startOffset": 22518,
            "title": "Vaccine"
        },
        {
            "endOffset": 29849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "The corresponding author (AHF) had full access to all the data in the study and final responsibility for the decision to submit for publication.",
            "startOffset": 29705,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 31048,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "There was also one severe AE, a soft tissue injury due to bicycle accident.",
            "startOffset": 30973,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 44487,
            "parents": [],
            "secId": "s0105",
            "sentence": "Vaxxas Pty Ltd, Brisbane, QLD 4102, Australia (ACTRN12616000880448).",
            "startOffset": 44419,
            "title": "Funding"
        },
        {
            "endOffset": 22517,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 22516,
                    "startOffset": 22512
                }
            },
            "secId": "s0020",
            "sentence": "Preclinical and in vitro studies demonstrated that approximately 20% (i.e. approximately 8 \u00b5g) of the vaccine was delivered into the skin, with the rest of the material remaining on the base of the NP [17].",
            "startOffset": 22311,
            "title": "Vaccine"
        },
        {
            "endOffset": 35017,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Most subjects (55%) preferred the NP compared to their previous experience of N&S injection, which was preferred by 24%, with the remaining subjects having no preference or not indicating a preference.",
            "startOffset": 34816,
            "title": "Acceptability questionnaire and interviews"
        },
        {
            "endOffset": 24448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The trial was registered with Australian New Zealand Clinical Trials Registry (ANZCTR.org.au), trial ID ACTRN12616000880448.",
            "startOffset": 24324,
            "title": "Trial subjects and study design"
        },
        {
            "endOffset": 42038,
            "parents": [],
            "secId": "s0085",
            "sentence": "Finally, although MAPs offer the potential for enhanced vaccine thermostability, this was not explored in detail in this study.",
            "startOffset": 41911,
            "title": "Discussion"
        },
        {
            "endOffset": 32111,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The erythema seen with the placebo NPs decreased steadily following removal of the NP, but persisted longer with the HA-NPs, with significantly higher erythema scores for the HA-NPs compared with the placebo at all timepoints from day 3 onwards after application (Fig. 4C).",
            "startOffset": 31838,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 28601,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The HAI titre was the reciprocal of the highest dilution of the sera that completely inhibited agglutination of TRBC by the virus.",
            "startOffset": 28471,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 19699,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19698,
                    "startOffset": 19695
                }
            },
            "secId": "s0005",
            "sentence": "Several groups are developing microarray patches (MAPs) for vaccine delivery to overcome these limitations [1].",
            "startOffset": 19588,
            "title": "Introduction"
        },
        {
            "endOffset": 31690,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In contrast, the skin response following HA-coated NP application peaked at day 3 and faded between day 7 and day 28.",
            "startOffset": 31573,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 30070,
            "parents": [],
            "secId": "s0055",
            "sentence": "Thirteen subjects out of 74 volunteers screened were not enrolled into the study (Fig. 2).",
            "startOffset": 29980,
            "title": "Results"
        },
        {
            "endOffset": 35168,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Reasons for opting for N&S were to avoid the red mark left by the NP, or due to itching at the application site, or because the N&S was more familiar.",
            "startOffset": 35018,
            "title": "Acceptability questionnaire and interviews"
        },
        {
            "endOffset": 43206,
            "parents": [],
            "secId": "s0085",
            "sentence": "In addition, NPs are now produced using medical-grade synthetic polymers rather than silicon, reducing the cost of goods of MAP production significantly.",
            "startOffset": 43053,
            "title": "Discussion"
        },
        {
            "endOffset": 29704,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Vaxxas served as the sponsor and took main responsibility for design and execution of the study.",
            "startOffset": 29608,
            "title": "Role of the funding source"
        },
        {
            "endOffset": 40568,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 40567,
                    "startOffset": 40563
                }
            },
            "secId": "s0085",
            "sentence": "Similar results were seen with the MN and HAI assays, although the MN GMTs were higher than the HAI titres, as has been observed by other groups [22].",
            "startOffset": 40418,
            "title": "Discussion"
        },
        {
            "endOffset": 27560,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Acceptability data were collected via an investigator-blinded, semi-structured interview (Supplementary Table 4) with open questions conducted between 1 and 2 h post vaccination and again at the end of study.",
            "startOffset": 27352,
            "title": "Qualitative acceptability assessment"
        },
        {
            "endOffset": 39498,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 39439,
                    "startOffset": 39434
                },
                "b0045": {
                    "endOffset": 39439,
                    "startOffset": 39434
                }
            },
            "secId": "s0085",
            "sentence": "The short wear time for NPs (2 min) could be particularly advantageous in this regard, making it more acceptable to vaccinees and healthcare systems than MAPs with longer wear times (20 min\u20136 h) [8,9], as it would be less disruptive to standard work patterns.",
            "startOffset": 39239,
            "title": "Discussion"
        },
        {
            "endOffset": 20687,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 20630,
                    "startOffset": 20623
                },
                "b0055": {
                    "endOffset": 20630,
                    "startOffset": 20623
                },
                "b0060": {
                    "endOffset": 20630,
                    "startOffset": 20623
                },
                "b0065": {
                    "endOffset": 20630,
                    "startOffset": 20623
                },
                "b0070": {
                    "endOffset": 20630,
                    "startOffset": 20623
                },
                "b0075": {
                    "endOffset": 20656,
                    "startOffset": 20652
                }
            },
            "secId": "s0005",
            "sentence": "In preclinical studies, the NP has been shown to deliver vaccine to the viable epidermis and dermis, and to be dose-sparing [10\u201314] and adjuvant sparing [15] compared with N&S IM delivery.",
            "startOffset": 20499,
            "title": "Introduction"
        },
        {
            "endOffset": 26360,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All NP applications were performed by the same nurse following training.",
            "startOffset": 26288,
            "title": "Study procedures"
        },
        {
            "endOffset": 26183,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Two NPs were administered to deliver the 15 \u00b5g dose, applied to the same site, at least 4 cm apart.",
            "startOffset": 26084,
            "title": "Study procedures"
        },
        {
            "endOffset": 31346,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Examples of application site reactions and resolution following application of a placebo (excipient-coated) NP and vaccine-coated NP are shown in Fig. 3.",
            "startOffset": 31193,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 32465,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Mild erythema was observed around the IM injection site on the day of injection, but in general the IM injections were well tolerated.",
            "startOffset": 32331,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 22826,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Following coating, NPs were placed into aluminium MediCan containers (Amcor, UK), foil-sealed, and stored at 2\u20138 \u00b0C before use (Fig. 1C).",
            "startOffset": 22689,
            "title": "Vaccine"
        },
        {
            "endOffset": 34643,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Only one subject experienced pain later than 10 min after vaccination, recording a score of \u20182\u2019 at 1 h in the NP-HA/FA group.",
            "startOffset": 34518,
            "title": "Pain at application site"
        },
        {
            "endOffset": 33840,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Self-reported pain scores 10 min after NP application or IM injection were low overall (Fig. 5).",
            "startOffset": 33744,
            "title": "Pain at application site"
        },
        {
            "endOffset": 19796,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 19795,
                    "startOffset": 19792
                }
            },
            "secId": "s0005",
            "sentence": "Various MAP formats have been tested extensively for vaccine delivery in preclinical models [2].",
            "startOffset": 19700,
            "title": "Introduction"
        },
        {
            "endOffset": 30711,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Headaches were the most common AE considered to be related to treatment, reported by 6 (13%) subjects receiving vaccine and 2 (13%) subjects in the placebo groups.",
            "startOffset": 30548,
            "title": "Summary of adverse events"
        },
        {
            "endOffset": 21006,
            "parents": [],
            "secId": "s0005",
            "sentence": "The safety and tolerability of the NP (without vaccine) was recently evaluated in humans.",
            "startOffset": 20917,
            "title": "Introduction"
        },
        {
            "endOffset": 44412,
            "parents": [],
            "secId": "s0100",
            "sentence": "The University of Sydney received funds from Vaxxas Pty Ltd for time spent to undertake training and analysis of qualitative data.",
            "startOffset": 44282,
            "title": "Declaration of interests"
        },
        {
            "endOffset": 37684,
            "parents": [],
            "secId": "s0085",
            "sentence": "We decided to study local skin responses in detail to understand their impact on the acceptability of vaccination by NPs.",
            "startOffset": 37563,
            "title": "Discussion"
        },
        {
            "endOffset": 43052,
            "parents": [],
            "secId": "s0085",
            "sentence": "A new method is used for NP vaccine coating which targets the tips of the microprojections, rather than the whole NP (as in this study), so that >80% of the vaccine payload is delivered to the skin (unpublished data); the current, relatively low delivery efficiencies obtained with the original version of the device as used in this study were an obvious limitation to the technology.",
            "startOffset": 42668,
            "title": "Discussion"
        },
        {
            "endOffset": 21647,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The applicator delivered NPs onto the skin at a velocity of 20 m/s.",
            "startOffset": 21580,
            "title": "Nanopatch manufacture"
        },
        {
            "endOffset": 37370,
            "parents": [],
            "secId": "s0085",
            "sentence": "Therefore it is encouraging that no clinically significant local or systemic adverse events were observed that were considered to be related to NP vaccinations.",
            "startOffset": 37210,
            "title": "Discussion"
        },
        {
            "endOffset": 43934,
            "parents": [],
            "secId": "s0095",
            "sentence": "GJF, JH, and AHF wrote the manuscript with significant contributions from KW, CMJ and IHF.",
            "startOffset": 43844,
            "title": "Contributors"
        },
        {
            "endOffset": 31503,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The initial erythema associated with placebo NP application typically faded to an area of mild discolouration between 2 h and day 3 after removal of the NP.",
            "startOffset": 31347,
            "title": "NP-application-site reactogenicity and resolution"
        },
        {
            "endOffset": 43734,
            "parents": [],
            "secId": "s0090",
            "sentence": "The results suggest that the NP has the potential to be an effective approach for vaccination with seasonal influenza and other vaccines.",
            "startOffset": 43597,
            "title": "Conclusion"
        },
        {
            "endOffset": 19329,
            "parents": [],
            "secId": "s0005",
            "sentence": "Most vaccinations are performed by injection using the needle and syringe (N&S).",
            "startOffset": 19249,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X1830673X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Germain J.P.",
                "initial": "G.J.P.",
                "last": "Fernando"
            },
            {
                "email": null,
                "first": "Julian",
                "initial": "J.",
                "last": "Hickling"
            },
            {
                "email": null,
                "first": "Cesar M.",
                "initial": "C.M.",
                "last": "Jayashi Flores"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Griffin"
            },
            {
                "email": null,
                "first": "Christopher D.",
                "initial": "C.D.",
                "last": "Anderson"
            },
            {
                "email": null,
                "first": "S. Rachel",
                "initial": "S.R.",
                "last": "Skinner"
            },
            {
                "email": null,
                "first": "Cristyn",
                "initial": "C.",
                "last": "Davies"
            },
            {
                "email": null,
                "first": "Katey",
                "initial": "K.",
                "last": "Witham"
            },
            {
                "email": null,
                "first": "Melinda",
                "initial": "M.",
                "last": "Pryor"
            },
            {
                "email": null,
                "first": "Jesse",
                "initial": "J.",
                "last": "Bodle"
            },
            {
                "email": null,
                "first": "Steve",
                "initial": "S.",
                "last": "Rockman"
            },
            {
                "email": null,
                "first": "Ian H.",
                "initial": "I.H.",
                "last": "Frazer"
            },
            {
                "email": "aforster@vaxxas.com",
                "first": "Angus H.",
                "initial": "A.H.",
                "last": "Forster"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.05.053",
        "firstpage": "3779",
        "issn": "0264410X",
        "keywords": [
            "Clinical trial",
            "Influenza",
            "Microarray patch",
            "Microneedle patch",
            "Nanopatch",
            "Transcutaneous vaccination"
        ],
        "lastpage": "3788",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch\u2122)"
    }
}